Skip to content

Muthu Parpam with Brahmi Nei (internal) and Siriya Bringamalaha Thailam (oil bath) for Attention Deficit Hyperactivity Disorder in Children.

Clinical Evaluation of Siddha Management of Muthu Parpam with Brahmi Nei (internal) and Siriya Bringamalaha Thailam (oil bath) for Alathidu Sanni (Attention Deficit Hyperactivity Disorder) in Children. - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/05/067754
Enrollment
20
Registered
2024-05-21
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F901- Attention-deficit hyperactivity disorder, predominantly hyperactive type

Interventions

Intervention1: Muthu Parpam With Brahmi Nei (internal) Siriya Bringamalaha Thailam (oilbath): Internal-Bid after food Dose vary with age for 60 days External-Oil bath (4 days once) for 60 days Control

Sponsors

National Institute of Siddha
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Meets the diagnostic symptoms of (Any of the three or above) 1. Lack of concentration 2. Talking incessantly 3. Blurting things out 4. Frequent jumping from one task to another 5. Being easily distracted 6. Hyperactivity 7. Trouble sitting still 8. Inability to react to other people’s emotions or feelings.

Exclusion criteria

Exclusion criteria: 1. H/O Seizure disorder 2. K/C/O Autistic spectrum disorder 3. Auditory and visual processing disorder. 4. Neurodegenerative disorder. 5. Post encephalitic disorder.

Design outcomes

Primary

MeasureTime frame
To assess the effectiveness of Muthu Parpam & Brahmi Nei (internal) and Siriya Bringamalaha Thailam (oil bath) for the management of Alathidu Sanni (Attention Deficit Hyperactive Disorder) in children by using Conner’s investigator rating scale and conner’s parent rating scale.Timepoint: Screening - 3 months Patient Enrolment - 6 months Trial Drug - 10 months Data Analysis - 2 month Follow up - 3 months

Secondary

MeasureTime frame
NilTimepoint: Nil

Countries

India

Contacts

Public ContactDr M Keerthana

National Institute of Siddha

gvennils@gmail.com9789093986

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026